25-Mar-2008
Bell Pottinger EXPANDS healthcare business
Summary
Bell Pottinger Group has formed Bell Pottinger Health, a new business dedicated to leading the expansion of its health franchise with Shipra Singh newly hired as Managing Director. Simultaneously the company has brought in a life science investor relations team led by Mike Wort.
Last Updated: 27-Aug-2010
Bell Pottinger Group has formed Bell Pottinger Health, a new business dedicated to leading the expansion of its health franchise with Shipra Singh newly hired as Managing Director. Simultaneously the company has brought in a life science investor relations team led by Mike Wort.
Bell Pottinger Health, which will report to Kevin Murray, Chairman of Bell Pottinger Group, will be led by De Facto Communications CEO Richard Anderson in the role of Chairman and by Shipra Singh, formerly of Hill & Knowlton, as Managing Director. The new agency, which will work in conjunction with De Facto, is in the process of establishing an international footprint, reflecting the global needs of clients in the pharmaceutical sector. The dedicated investor relations team led by Mike Wort will be merged into De Facto to add a valuable new resource for the company’s clients.
Says Richard Anderson: “Bell Pottinger already has a significant presence in the health sector especially with those involved in the commissioning and delivery of healthcare services and, through De Facto, in the development of new medicines and health technologies. By creating a new and focused communications business we can extend the reach of Bell Pottinger across a much broader health spectrum to include disease prevention, diagnosis and treatments. Our insights and experience in healthcare delivery and drug development combined with the new team that we will be building will enable us to bring a compelling new offering to our clients. In Shipra Singh and Mike Wort we have experts who will work with me to draw upon the strengths and talent from across the Bell Pottinger Group as we build the new business.”
Shipra Singh adds: “Bell Pottinger Health has one of the most comprehensive healthcare offers in our industry, covering everything from pharmaceutical and OTC communications to specialist healthcare services like clinical trial recruitment and retention, market access and re-imbursement, and financial communications. I look forward to playing my part in its continued development.”
“By joining with De Facto we bring to the Bell Pottinger Group an established team of Investor Relations specialists with a focus on SME’s in the life science sector. The leadership position that De Facto has in life scientific and corporate communications mirrors our philosophy of making complex technology, clinical trial data and merger and acquisition strategies understandable to all City audiences including the buy and sell side analysts, the financial media and the trade and technical press. We complement perfectly the activities of Bell Pottinger Corporate and Financial who have an impressive reputation for providing Investor Relations Services for mid and large cap companies,” commented Mike Wort.
Shipra Singh was previously Managing Director of Healthcare and Wellbeing at Hill & Knowlton, where she has worked since 2001. Shipra has specific expertise in both international and UK communications programmes and has worked with clients ranging from pharmaceutical companies, third party groups, and government to OTC manufacturers and retailers. In her 12 years in healthcare public relations Shipra has also worked on a number of issues based programmes including product withdrawals, licensing changes and communicating non optimal study results.
Mike Wort becomes the Managing Director of De Facto’s life science business while Anna Dunphy joins as Account Director. Following 20 years working in the pharmaceutical industry with Glaxo, SmithKline and Wellcome in various senior roles in the UK and overseas, Mike has dedicated his career to helping emerging companies communicate with financial audiences in the UK and across Europe. His last role in industry was Investor Relations Manager at Wellcome, following which he co-founded Europe’s first specialist investor relations consultancy dedicated to the life sciences industry, which was financed by De Facto. During his career in financial communications he has been involved in raising more than £2.5bn to date for the companies that he has worked with.
-Ends-
Bell Pottinger Health is part of the Bell Pottinger Group www.bell-pottinger.co.uk which is the No.1 public relations group in the UK which is owned by Chime Communications plc.
The Bell Pottinger Health website www.bellpottingerhealth.com will be launching shortly.
Contact:
Richard Anderson
De Facto Communications
T: +44 (0)20 7861 3838
E: r.anderson@defacto.com
Bell Pottinger Health, which will report to Kevin Murray, Chairman of Bell Pottinger Group, will be led by De Facto Communications CEO Richard Anderson in the role of Chairman and by Shipra Singh, formerly of Hill & Knowlton, as Managing Director. The new agency, which will work in conjunction with De Facto, is in the process of establishing an international footprint, reflecting the global needs of clients in the pharmaceutical sector. The dedicated investor relations team led by Mike Wort will be merged into De Facto to add a valuable new resource for the company’s clients.
Says Richard Anderson: “Bell Pottinger already has a significant presence in the health sector especially with those involved in the commissioning and delivery of healthcare services and, through De Facto, in the development of new medicines and health technologies. By creating a new and focused communications business we can extend the reach of Bell Pottinger across a much broader health spectrum to include disease prevention, diagnosis and treatments. Our insights and experience in healthcare delivery and drug development combined with the new team that we will be building will enable us to bring a compelling new offering to our clients. In Shipra Singh and Mike Wort we have experts who will work with me to draw upon the strengths and talent from across the Bell Pottinger Group as we build the new business.”
Shipra Singh adds: “Bell Pottinger Health has one of the most comprehensive healthcare offers in our industry, covering everything from pharmaceutical and OTC communications to specialist healthcare services like clinical trial recruitment and retention, market access and re-imbursement, and financial communications. I look forward to playing my part in its continued development.”
“By joining with De Facto we bring to the Bell Pottinger Group an established team of Investor Relations specialists with a focus on SME’s in the life science sector. The leadership position that De Facto has in life scientific and corporate communications mirrors our philosophy of making complex technology, clinical trial data and merger and acquisition strategies understandable to all City audiences including the buy and sell side analysts, the financial media and the trade and technical press. We complement perfectly the activities of Bell Pottinger Corporate and Financial who have an impressive reputation for providing Investor Relations Services for mid and large cap companies,” commented Mike Wort.
Shipra Singh was previously Managing Director of Healthcare and Wellbeing at Hill & Knowlton, where she has worked since 2001. Shipra has specific expertise in both international and UK communications programmes and has worked with clients ranging from pharmaceutical companies, third party groups, and government to OTC manufacturers and retailers. In her 12 years in healthcare public relations Shipra has also worked on a number of issues based programmes including product withdrawals, licensing changes and communicating non optimal study results.
Mike Wort becomes the Managing Director of De Facto’s life science business while Anna Dunphy joins as Account Director. Following 20 years working in the pharmaceutical industry with Glaxo, SmithKline and Wellcome in various senior roles in the UK and overseas, Mike has dedicated his career to helping emerging companies communicate with financial audiences in the UK and across Europe. His last role in industry was Investor Relations Manager at Wellcome, following which he co-founded Europe’s first specialist investor relations consultancy dedicated to the life sciences industry, which was financed by De Facto. During his career in financial communications he has been involved in raising more than £2.5bn to date for the companies that he has worked with.
-Ends-
Bell Pottinger Health is part of the Bell Pottinger Group www.bell-pottinger.co.uk which is the No.1 public relations group in the UK which is owned by Chime Communications plc.
The Bell Pottinger Health website www.bellpottingerhealth.com will be launching shortly.
Contact:
Richard Anderson
De Facto Communications
T: +44 (0)20 7861 3838
E: r.anderson@defacto.com
